NASDAQ:ELTX Elicio Therapeutics (ELTX) Stock Price, News & Analysis $10.63 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$10.66 +0.02 (+0.24%) As of 05/15/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Elicio Therapeutics Stock (NASDAQ:ELTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Elicio Therapeutics alerts:Sign Up Key Stats Today's Range$10.48▼$11.0650-Day Range$9.91▼$13.5552-Week Range$5.15▼$14.93Volume119,030 shsAverage Volume131,491 shsMarket Capitalization$202.93 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingModerate Buy Company Overview Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y. Read More Elicio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreELTX MarketRank™: Elicio Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 719th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingElicio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialElicio Therapeutics has a consensus price target of $18.00, representing about 69.3% upside from its current price of $10.63.Amount of Analyst CoverageElicio Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Elicio Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elicio Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elicio Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElicio Therapeutics has a P/B Ratio of 118.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Elicio Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.42% of the float of Elicio Therapeutics has been sold short.Short Interest Ratio / Days to CoverElicio Therapeutics has a short interest ratio ("days to cover") of 11.62, which indicates bearish sentiment.Change versus previous monthShort interest in Elicio Therapeutics has recently increased by 14.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElicio Therapeutics does not currently pay a dividend.Dividend GrowthElicio Therapeutics does not have a long track record of dividend growth. News and Social Media1.0 / 5News Sentiment-0.36 News SentimentElicio Therapeutics has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Elicio Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.65% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.03% of the stock of Elicio Therapeutics is held by institutions.Read more about Elicio Therapeutics' insider trading history. Receive ELTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELTX Stock News HeadlinesElicio Therapeutics (NASDAQ:ELTX) Rating Lowered to Sell at Wall Street ZenMay 16 at 1:44 AM | americanbankingnews.comElicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 12, 2026 | markets.businessinsider.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 18 at 1:00 AM | Brownstone Research (Ad)Elicio Therapeutics (ELTX) Expected to Announce Quarterly Earnings on TuesdayMay 10, 2026 | americanbankingnews.comElicio Therapeutics to Present at the Bank of America Healthcare ConferenceApril 30, 2026 | globenewswire.comElicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running OutApril 29, 2026 | seekingalpha.comJonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX)April 19, 2026 | theglobeandmail.comElicio Therapeutics Reports Inducement GrantsApril 16, 2026 | globenewswire.comSee More Headlines ELTX Stock Analysis - Frequently Asked Questions How have ELTX shares performed this year? Elicio Therapeutics' stock was trading at $7.96 at the beginning of 2026. Since then, ELTX shares have increased by 33.5% and is now trading at $10.63. How were Elicio Therapeutics' earnings last quarter? Elicio Therapeutics, Inc. (NASDAQ:ELTX) issued its earnings results on Monday, May, 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.16. When did Elicio Therapeutics IPO? Elicio Therapeutics (ELTX) raised $40 million in an initial public offering (IPO) on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Elicio Therapeutics' major shareholders? Top institutional shareholders of Elicio Therapeutics include Renaissance Technologies LLC (0.64%), OMERS ADMINISTRATION Corp (0.06%) and HB Wealth Management LLC (0.06%). View institutional ownership trends. How do I buy shares of Elicio Therapeutics? Shares of ELTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elicio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA). Company Calendar Last Earnings5/11/2026Today5/18/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ELTX's financial health is in the Green zone, according to TradeSmith. ELTX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:ELTX CIK1555192 Webwww.angion.com Phone415-655-4899FaxN/AEmployeesN/AYear Founded2011Price Target and Rating Average Price Target for Elicio Therapeutics$18.00 High Price Target$20.00 Low Price Target$17.00 Potential Upside/Downside+69.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.57 million Net MarginsN/A Pretax MarginN/A Return on Equity-2,748.16% Return on Assets-151.12% Debt Debt-to-Equity Ratio5.75 Current Ratio2.24 Quick Ratio2.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book118.11Miscellaneous Outstanding Shares19,090,000Free Float13,618,000Market Cap$202.93 million OptionableNot Optionable Beta1.12 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ELTX) was last updated on 5/18/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThe filing was one thing. June 1 is another.The SpaceX filing got attention - but according to macroeconomic strategist Dr. Mark Skousen of The Oxford Clu...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
